Cellply selected as finalist at Lyfebulb Oncology Award

MONACO, PRINCIPALITY OF MONACO, NEW YORK, NY, and BOLOGNA, ITALY, March 1, 2018:

Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, have announced today that Cellply has been selected as one the eleven finalist companies for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. The Lyfebulb-Helsinn Innovation Summit & Award final event will be hosted on 26-27 March 2018, by Lyfebulb and Helsinn at the Monte-Carlo Bay Hotel and Resort, in Monaco, Principality of Monaco.

Read the full story here

Leave a Reply

Your email address will not be published. Required fields are marked *